Rocket Pharmaceuticals

Rocket Pharmaceuticals

RCKT· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock -72.1% in FY2025

Gaurav D. Shah, M.D. is the CEO of Rocket Pharmaceuticals and was paid $3.5M in FY2025 (Dec), down 49%.

Pay$100 in the stock at the end of FY20 → $6
CEO pay is from each Rocket Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Christopher StevensFY2025
  2. 2Gaurav D. Shah, M.D.FY2025
  3. 3Martin WilsonNot disclosed

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Rocket Pharmaceuticals paid its 2 named executives $7.1M in total in FY2025 (Dec). CEO Gaurav D. Shah, M.D. was paid $3.5M of that.

Name
Christopher StevensChief Operating OfficerNot disclosedNot disclosed
Gaurav D. Shah, M.D.Chief Executive Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2023 (Dec) proxy of Rocket Pharmaceuticals names 16 peer companies for pay. Among Rocket Pharmaceuticals and these peers, CEO pay was the highest of 4 and total shareholder return was 2nd highest of 4.

1st highest of 4in Rocket Pharmaceuticals and its pay peers, FY2023 (Dec) by CEO pay:

$3.6M$8.0M

2nd highest of 4in Rocket Pharmaceuticals and its pay peers, FY2023 (Dec) by total shareholder return:

$44$145

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board1

See all
  • Gotham Makker, M.D.Director · 6 yr on the boardIndependentCompensation, Research & Development—Paid as an executive

The board of the latest proxy (FY2024).

Activity

  1. Left the market25
  2. PayDEF 14A
  3. PayDEF 14A
  4. PayDEF 14A
  5. PayDEF 14A
  6. PayDEF 14A
  7. PayDEF 14A
  8. PayDEF 14A
  9. PayDEF 14A
  10. PayDEF 14A
  11. PayDEF 14A
  12. PayDEF 14A
  13. PayDEF 14A

Filings6

See all
Proxy statementDEF 14AApr 6, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 30, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KFeb 27, 2024FY2023